- Home
- PWM vs CALC Comparison
PWM vs CALC Comparison
Compare PWM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- CALC
- Stock Information
- Founded
- PWM 2018
- CALC 2011
- Country
- PWM Hong Kong
- CALC United States
- Employees
- PWM N/A
- CALC N/A
- Industry
- PWM
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- CALC Health Care
- Exchange
- PWM Nasdaq
- CALC Nasdaq
- Market Cap
- PWM 12.4M
- CALC 22.9M
- IPO Year
- PWM 2023
- CALC N/A
- Fundamental
- Price
- PWM $0.39
- CALC $1.58
- Analyst Decision
- PWM
- CALC Strong Buy
- Analyst Count
- PWM 0
- CALC 3
- Target Price
- PWM N/A
- CALC $16.33
- AVG Volume (30 Days)
- PWM 6.2M
- CALC 28.9K
- Earning Date
- PWM 07-07-2025
- CALC 08-11-2025
- Dividend Yield
- PWM N/A
- CALC N/A
- EPS Growth
- PWM N/A
- CALC N/A
- EPS
- PWM N/A
- CALC N/A
- Revenue
- PWM $639,912.00
- CALC N/A
- Revenue This Year
- PWM N/A
- CALC N/A
- Revenue Next Year
- PWM N/A
- CALC N/A
- P/E Ratio
- PWM N/A
- CALC N/A
- Revenue Growth
- PWM 83.60
- CALC N/A
- 52 Week Low
- PWM $0.31
- CALC $1.42
- 52 Week High
- PWM $2.70
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- PWM 49.95
- CALC 44.94
- Support Level
- PWM $0.33
- CALC $1.42
- Resistance Level
- PWM $0.78
- CALC $1.85
- Average True Range (ATR)
- PWM 0.06
- CALC 0.15
- MACD
- PWM 0.01
- CALC -0.01
- Stochastic Oscillator
- PWM 15.40
- CALC 37.21
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.